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ABSTRACT
Cardiac toxicity after conventional antineoplastic drugs 
(eg, anthracyclines) has historically been a relevant issue. 
In addition, targeted therapies and biological molecules 
can also induce cardiotoxicity. Immune checkpoint 
inhibitors are a novel class of anticancer drugs, distinct 
from targeted or tumour type-specific therapies. Cancer 
immunotherapy with immune checkpoint blockers (ie, 
monoclonal antibodies targeting cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4), programmed cell death 
1 (PD-1) and its ligand (PD-L1)) has revolutionised the 
management of a wide variety of malignancies endowed 
with poor prognosis. These inhibitors unleash antitumour 
immunity, mediate cancer regression and improve the 
survival in a percentage of patients with different types of 
malignancies, but can also produce a wide spectrum of 
immune-related adverse events. Interestingly, PD-1 and 
PD-L1 are expressed in rodent and human cardiomyocytes, 
and early animal studies have demonstrated that CTLA-4 
and PD-1 deletion can cause autoimmune myocarditis. 
Cardiac toxicity has largely been underestimated in 
recent reviews of toxicity of checkpoint inhibitors, but 
during the last years several cases of myocarditis and 
fatal heart failure have been reported in patients treated 
with checkpoint inhibitors alone and in combination. Here 
we describe the mechanisms of the most prominent 
checkpoint inhibitors, specifically ipilimumab (anti-
CTLA-4, the godfather of checkpoint inhibitors) patient 
and monoclonal antibodies targeting PD-1 (eg, nivolumab, 
pembrolizumab) and PD-L1 (eg, atezolizumab). We also 
discuss what is known and what needs to be done about 
cardiotoxicity of checkpoint inhibitors in patients with 
cancer. Severe cardiovascular effects associated with 
checkpoint blockade introduce important issues for 
oncologists, cardiologists and immunologists.
IntroductIon
Cardiovascular toxicity (left ventricular 
dysfunction and heart failure (HF), myocar-
dial ischaemia and infarction, hypertension, 
QT prolongation and arrhythmias, throm-
boembolism) caused by conventional anti-
neoplastic drugs remains a critical issue.1 2 
Cardiotoxicity may be reversible or irrevers-
ible and can occur soon after or after several 
months/years of treatment.3 Cardiac dysfunc-
tion caused by cytotoxic agents (eg, anthracy-
clines) has historically been the most relevant 
problem. However, targeted therapies and 
biological drugs affecting specific signalling 
pathways can also induce cardiotoxicity.1 2 4–6 
The development of immunotherapies in 
oncology over the past decade has revolu-
tionised the management of an increasing 
number of advanced-stage malignancies 
previously endowed with dismal prog-
nosis.7 8 Monoclonal antibodies (mAbs) 
targeting immune checkpoint molecules (eg, 
cytotoxic T lymphocyte-associated antigen 
4 (CTLA-4), programmed cell death 1 (PD-1) 
and its ligand (PD-L1)) have shown unprec-
edented success in a broad spectrum of 
solid9–18 and haematological tumours.19–23 
Several checkpoint inhibition strategies 
have been developed.24–26 The first and most 
widely mAb used is ipilimumab, which targets 
CTLA-4 and was introduced in 2010 for 
the treatment of melanoma. More recently 
several mAbs targeting PD-1 (nivolumab, 
pembrolizumab) and PD-L1 (atezolizumab, 
durvalumab, avelumab) have been intro-
duced for the treatment of different types of 
cancer.25 27 28 All these drugs have improved 
the prognosis in melanoma and in other 
cancer types endowed with poor prognosis.
Unfortunately, these compounds can 
produce a wide spectrum of immune-re-
lated adverse events (IRAEs).29–32 Interest-
ingly, PD-1 and PD-L1 can be also expressed 
in rodent and human cardiomyocytes,33–36 
and animal studies have demonstrated that 
CTLA-4 and PD-1 deletion can cause autoim-
mune myocarditis.37–41 During the last years 
several cases of myocarditis and fatal HF have 
been reported in patients with cancer 
treated with immune checkpoint inhibitors 
(ICIs).16 30 36 42–44 Severe cardiovascular effects 
associated with checkpoint blockade intro-
duce important issues for oncologists, cardi-
ologists and immunologists.
ImmunIty and cancer: pathophysIology of 
cancer ImmunosurveIllance
As cancer arises and progresses, malignant 
cells accumulate genetic alterations resulting 
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in the expression of several neoantigens.45 The innate 
and adaptive immune responses initially prevent tumour 
outgrowth. However, cancer cells can escape the immune 
response (immunosurveillance) by selection of non-im-
munogenic tumour cells (immunoediting) or suppression 
of immune responses.46 47 For decades, immunologists 
and oncologists have attempted to stimulate antitumour 
immune responses to fight cancer. These initial attempts 
displayed marginal success for a number of reasons. In 
particular, several inhibitory pathways, such as CTLA-4, 
PD-1 and PD-L1, profoundly dampen the antitumour 
functions of T lymphocytes.48 These inhibitory pathways 
play pivotal roles in the maintenance of peripheral toler-
ance and the prevention of autoimmune diseases.33 49 
Tumours exploit these and many other inhibitory path-
ways to escape T cell-mediated tumour-specific immunity 
(figures 1 and 2). The pioneering work of Allison and 
coworkers led to the discovery that activation of these 
checkpoint inhibitors is a fundamental tool by which 
tumour cells evade the immune system.8 50 Blockade of 
these immune checkpoints with specific mAbs (eg, anti-
CTLA-4, anti-PD-1, anti-PD-L1) has recently revolution-
ised the entire branch of immunotherapy of a wide spec-
trum of tumours.51 52
anti-ctla-4: the first generation of checkpoint inhibitors
The development of blocking mAbs against immune 
checkpoint molecules is based on the role of these mole-
cules as coinhibitory receptors of T lymphocytes. Indeed, 
the activation of naïve T lymphocytes requires antigen 
presentation by dendritic cells (DCs) to T cells through 
the interaction of major histocompatibility complex 
Figure 1 Mechanism of CTLA-4-induced immunosuppression. (A) Cancer cells synthesise and release neoantigens (dots 
of different colours) that are captured by APCs. These cells present peptides in the context of MHC I molecules/TCRs on the 
surface of CD8+ cytotoxic T cells within lymph nodes. APCs can also present peptides bound to MHC II molecules to CD4+ 
T helper cells. T cell activation on TCR signalling requires costimulatory signals transmitted via CD28, which is activated by 
binding to CD80, and/or CD86, on the surface of APCs. Activated T cells upregulate CTLA-4, which competes with CD28 for 
binding to CD80 and/or CD86. The interaction of CTLA-4 with CD80 or CD86 results in inhibitory signalling promoting tumour 
growth. The immunosuppressive activity of CTLA-4 is mediated by downregulation of Th cells and enhancement of Treg cells. 
(B) CTLA-4 blockade by ipilimumab results in a broad enhancement of immune responses against neoantigen expressing 
tumour cells, which results in killing of tumour cells. APC, antigen presenting cell; CTLA-4, cytotoxic T lymphocyte-associated 
antigen 4; TCR, T cell receptor; Th cells, helper CD4+ T cells; Treg, regulatory T cell.
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(MHC) and T cell receptor (TCR) (signal 1). The 
process of T cell activation is strengthened by costimu-
latory signals.53 Receptors delivering coinhibitory signals 
(eg, CTLA-4, PD-1) function as immune checkpoints and 
play a role in maintaining tolerance and in preventing 
autoimmunity.49 54 55 The pathways involving either CD80 
(also known as B7.1) or CD86 (also known as B7.2), plus 
either CD28 or CTLA-4, are crucial in T cell activation 
and tolerance (figure 1).
CTLA-4, expressed almost exclusively on T cells, modu-
lates the amplitude of early stages of T cell activation.56 57 
CTLA-4 competes with CD28 for binding to B7.1 and/or 
B7.2.58 CD28 and CTLA-4 share identical ligands, CD80 
and/or CD86.59–62 Overexpression of CTLA-4 on acti-
vated T cells dampens their activation competing CD28 in 
binding CD80 and/or CD86. The crucial role of CTLA-4 
was demonstrated by the lethal immune hyperactivation 
phenotype of Ctla-4 knockout mice.54 55 The immunosup-
pressive activity of CTLA-4 is mediated by downmodula-
tion of helper CD4+ T cell and enhancement of regulatory 
T cell (Treg) activity.63 64
The discovery of these immunoregulating CTLA-4 func-
tions as a negative regulator of immune responses led to a 
radical shift in cancer immunotherapy: removal of inhibi-
tory signals that block antitumour T cell responses rather 
than direct activation of the immune system.50 Indeed, 
mice bearing immunogenic tumours and treated with 
an anti-CTLA-4 antibody showed an efficient antitumour 
response.65 This seminal observation led to the develop-
ment of a fully human mAb anti-CTLA-4 (ipilimumab), 
which was the prototype mAb to demonstrate a survival 
benefit for patients with metastatic melanoma,66 and it 
Figure 2 Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. (A) Tumour 
neoantigens (dots of different colours) released by cancer cells are captured by APCs. These cells present peptides in the 
context of MHC molecules/TCRs on the surface of CD8+ cytotoxic T cells. PD-1 is induced on T cells on activation through 
the TCR and through several cytokines. Tumour cells and other cells in the tumour microenvironment (eg, endothelial cells, 
mast cells) can express high levels of PD-L1 and/or PD-L2 that binds to PD-1 on T cells, resulting in inhibitory checkpoint 
signalling that decreases cytotoxicity and leads to T cell exhaustion. Recent evidence suggests that murine and human cancer 
cell subpopulations can express PD-1 and promote tumour growth. (B) PD-1 blocking antibodies (nivolumab, pembrolizumab, 
pidilizumab and so on) inhibit the interaction of PD-1 with both PD-L1 and PD-L2, resulting in enhanced T cell cytotoxicity, 
TAM activity, increased cytokine production, and ultimately killing of tumour cells. PD-L1+ tumour cells can also induce T cell 
apoptosis, anergy, functional exhaustion and interleukin-10 production. Anti-PD-L1 antibodies (atezolizumab, durvalumab, 
avelumab) have similar effects, but only inhibit the interaction between PD-L1 and PD-1. PD-1, programmed cell death 1; PD-
L1, programmed cell death ligand 1; TAM, tumour-associated macrophage; TCR, T cell receptor. 
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was approved by the Food and Drug Administration in 
2010 and the European Medicines Agency in 2011.
anti-pd-1 pathway: the second generation of checkpoint 
inhibitors
The immune system has developed several coinhibitory 
pathways to maintain T cell tolerance and to prevent auto-
immunity.26 67 The pathway consisting of PD-1 (also called 
CD279) and its ligands, PD-L1 (B7-H1 or CD274) and 
PD-L2 (B7-DC or CD276), is another important target to 
stimulate antitumour immune responses. Several mAbs 
targeting PD-1 and PD-L1 have been developed based on 
the role of these checkpoint molecules as coinhibitory 
receptors of T cell activation (figure 2 and table 1). mAbs 
against PD-1 and/or PD-L1 restore antitumour immune 
responses and have shown favourable clinical responses 
across various cancers.68
BTLA, B and T lymphocyte attenuator; CTLA-4, cyto-
toxic T lymphocyte-associated antigen 4; LAG-3, lympho-
cyte-activated gene-3; PD-1, programmed cell death 1; 
PD-L1, programmed cell death ligand 1; TIGIT, T cell 
immunoreceptor with Ig and ITIM domains; TIM-3, T 
cell immunoglobulin and mucin-containing protein 3; 
VISTA, V-domain Ig suppressor of T cell activation.
PD-1 is induced on T cells on activation through the 
TCR and cytokines.69 PD-1 is expressed at low levels on T 
cells in the thymus, activated natural killer (NK) cells, B 
cells, monocytes, tumour-associated macrophage (TAM), 
immature Langerhans cells and cardiomyocytes.35 69–71 
During T cell activation, PD-1 is translocated to TCR 
microclusters.72 Engagement of PD-1 by PD-L1 inhibits 
the activation of TCR proximal kinases.73 PD-1 ligation 
inhibits T cell–APC contacts and thereby contributes to 
the cessation of T cell effector functions. The role of PD-1 
in peripheral tolerance was demonstrated by the devel-
opment of lupus-like glomerulonephritis and arthritis,49 
as well as in dilated cardiomyopathy in PD-1-deficient 
mice.33
PD-L1 and PD-L2, the ligands of PD-1, display different 
expression.69 74 PD-L1 is constitutively expressed at low 
levels on both professional APCs and non-professional 
Table 1 Immune checkpoint inhibitors under preclinical and clinical development
Target Agent Antibody Manufacturer
CTLA-4 Ipilimumab Human IgG1 Bristol-Myers Squibb
PD-1 Nivolumab Human IgG4 Bristol-Myers Squibb
Pembrolizumab Humanised IgG4 Merck
MEDI0680 Humanised MedImmune
REGN2810 Human IgG4 Regeneron/Sanofi
PDR001 Humanised IgG4 Novartis
BGB-A317 Humanised BeiGene
Pidilizumab Humanised IgG1 Medivation/CureTech
AMP-224 PD-L2 IgG2a fusion protein GSK
AMP-514 PD-L2 fusion protein GSK
SHR-1210 Human IgG4 Incyte/Jiangsu
JS001 Humanised Shanghai Junshi Biosciences
Tsr-042 Humanised Tesaro
PD-L1 Atezolizumab Humanised IgG1 Genentech/Roche
Durvalumab Human IgG1 MedImmune/AstraZeneca
Avelumab Human IgG1 Merck Serono/Pfizer
BMS-936559 Human IgG4 Bristol-Myers Squibb
LY3300054 Not available Eli Lilly
MEDI4736 Humanised IgG1 AstraZeneca
KNO35 Not available 3D Medicines
PD-L2 rHIgM12B7 Mayo Clinic/NCI
TIM-3 Anti-TIM-3 antibody
LAG-3 Dual anti-LAG-3/anti-PD-1 
antibody
TIGIT Anti-TIGIT antibody
BTLA Anti-BTLA antibody
VISTA Anti-VISTA antibody
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APCs, as well as on non-haematopoietic cells (ie, endo-
thelial cells, pancreatic islet cells, testes and eye).75 PD-L1 
is also expressed by cardiomyocytes.36 70 PD-L1 pathway 
suppresses effector T cells, maintains self-tolerance and 
promotes the resolution of inflammation.
The expression of PD-L1 and, to a lesser extent, PD-L2 
in several tumours11 75 76 stimulated the exploitation of 
the PD-1–PD-L1 pathway in cancer immunotherapy. In 
fact, PD-L1 delivers antiapoptotic signals to cancer cells 
and prevents immune-mediated cancer cell killing.77 
Cancer cells dampen the host immune response through 
the upregulation of PD-L1 and PD-L2 in tumour micro-
environment and their ligation to PD-1 expressed by 
tumour-specific CD8+ T cells. PD-L1 and PD-L2 can be 
upregulated by cancer cells through several cytokines 
(interferon (IFN), tumour necrosis factor-α (TNF-α) 
and vascular endothelial growth factor (VEGF)). PD-L1 
expression is also modulated by epigenetic mechanisms 
through microRNAs.78
In tumour microenvironment, tumour neoantigens 
released by dying cancer cells activate T cells that over-
express PD-1. Recent evidence indicates that mouse 
and human TAM express PD-1.71 TAM PD-1 expression 
increases with increasing disease stage in human tumours 
and dampens macrophage phagocytosis of tumour cells. 
These events result in the activation of PD-1–PD-L1/
PD-L2 inhibitory mechanism(s) leading to selective inhi-
bition of tumour-specific T cells and TAM. Therefore, 
targeting of the PD-1/PD-L1 checkpoint pathway with 
mAbs results in the expansion of tumour-infiltrating 
CD8+ T cells, which recognise tumour antigens.71 79 CD8+ 
T cells at the invasive tumour front progressively increase 
during immunotherapy and correlate with a reduction in 
tumour size.12 These findings suggest that anti-PD-1 anti-
body increases CD8+ memory T cell and TAM functions in 
the tumour microenvironment.71 80 In addition, they also 
suggest that, although anti-PD-1/PD-L1 inhibitors are 
administered systematically, their mechanism of action is 
presumably locally active in cancer tissues.
the new generation of checkpoint inhibitors
Immunotherapy targeting CTLA-4 (ipilimumab), PD-1 
(nivolumab and pembrolizumab) and PD-L1 (atezoli-
zumab, avelumab, durvalumab) has revolutionised 
the management of several tumours.12 81–85 Check-
point inhibitors provide clinical benefits for a subset of 
patients with a wide range of solid (melanoma, non-small 
cell lung cancer (NSCLC), renal carcinoma, ovarian 
cancer)9 85 86 and haematological tumours (Hodgkin’s 
lymphoma, primary lymphoma, chronic lymphocytic 
leukaemia, multiple myeloma).19–23
Despite these promising results, dramatic responses 
are confined to a minority of patients.28 87 88 This is likely 
due to the complex network of immunosuppressive path-
ways in tumour microenvironment, which are unlikely 
overcome by the blockage of a single signalling check-
point molecule. In fact, combined anti-CTLA-4 and anti-
PD-1 blockade further enhances antitumour activity and 
patient survival.66 83 89 90 In addition, combination of four 
different types of immunotherapies eradicated several 
experimental tumours viewed as intractable.91 A new 
generation of checkpoint inhibitors, beyond CTLA-4, 
PD-1 and PD-L1, are under preclinical and clinical devel-
opment for safer and more effective treatment of human 
cancers (table 1).
The T cell immunoglobulin and mucin-containing 
protein 3 (TIM-3), expressed on Treg cells, monocytes/
macrophages and APCs, regulate their functions.92 93 
Anti-TIM-3 inhibits tumour growth.92 The lymphocyte-ac-
tivated gene-3 (LAG-3, CD223) is expressed by CD4+ and 
CD8+ T cells, Treg and Tr1 cells.94–96 LAG-3 blockade 
synergises with PD-1 inhibition to induce tumour regres-
sion.97 98
The T cell immunoreceptor with Ig and ITIM domains 
(TIGIT) is a novel member of the immunoglobulin 
superfamily expressed on activated T cells, Tregs, NK 
and natural killer t cells (NKT) cells.99 100 Similar to 
PD-1, TIM-3 and LAG-3, TIGIT is upregulated on T 
cells in cancer.101 TIGIT and PD-1 coblockade inhibits 
tumour growth in mice.101 B and T lymphocyte attenu-
ator (BTLA), structurally related to CTLA-4 and PD-1, 
is expressed on B cells, αβ and γδ T cells and DCs.102 103 
BTLA blockade induces tumour regression in mice.104
The V-domain Ig suppressor of T cell activation 
(VISTA), also known as PD-1 homologue, is expressed on 
neutrophils, monocytes/macrophages, DCs, Myeloidden-
dritic cells (MDSDs) and Treg cells, and at lower levels 
on CD4+ and CD8+ T cells.105 VISTA blockade, combined 
with a peptide vaccine, induces tumour regression in a 
melanoma model.106
These novel checkpoint inhibitors, alone or in combi-
nation, restore antitumour immunological responses in 
preclinical models. It is likely that immunotherapeutic 
approaches of human cancers may enlist the combined 
use of several checkpoint inhibitors.91 The assessment of 
adverse events, including cardiac toxicity, of these novel 
checkpoint regulators, alone and in combination, will be 
of fundamental clinical relevance.
Iraes assocIated wIth checkpoInt InhIbItors
Due to the pivotal role played by immune checkpoints 
in the maintenance of self-tolerance, their therapeutic 
blockade can alter immunological tolerance,87 and give 
rise to autoimmune or inflammatory side effects, termed 
‘immune-related adverse events’.31 107–109 IRAEs associ-
ated with the use of ipilimumab were already evident in 
phase I studies, but now their incidence and severity are 
well-recognised.66 110 IRAEs are common, usually revers-
ible and not severe in most patients.29 However, endo-
crinopathies (6%–8% of patients)111 are associated with 
a high risk of irreversible toxicity. They are caused by the 
immune infiltration into the thyroid or pituitary glands, 
resulting in thyroiditis or hypophysitis, respectively.112
PD-1 and PD-L1 blocking agents display different adverse 
effect profiles compared with ipilimumab.107 The most 
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common adverse events are mild fatigue, rash, pruritus 
and diarrhoea.87 The incidence of IRAEs seems to be 
lower with anti-PD-1 therapy than with ipilimumab.9 66 In 
general, IRAEs caused by ICIs resemble the autoimmune 
manifestations observed in PD-1-deficient mice.33 49 113 
Even though adverse events with combined checkpoint 
inhibitors are reported as well-tolerated,114 115 combina-
tion of ipilimumab plus nivolumab requires discontinua-
tion of therapy in nearly 40% of patients.89 90 116 IRAEs can 
affect nearly every organ in association with checkpoint 
inhibitors (figure 3). Knowledge of the early-onset and 
late-onset toxic effects associated with checkpoint inhib-
itors, as well as effective algorithms for the identification 
and management of these effects, will be fundamental to 
optimise the safety and efficacy of these immunothera-
pies.117 Finally, the long-term impact of immune check-
point blockers on quality of life must be evaluated in 
future studies.
cardIac toxIcIty In pd-1-defIcIent and ctla-4-
defIcIent anImals
PD-L1 is expressed in human34 and murine heart.35 
Freeman and colleagues concluded that PD-L1 may 
regulate potentially autoreactive lymphocytes at 
effector sites, thus playing a role in limiting activities 
of T cells in the heart, where PD-L1 is highly expressed. 
Nishimura and coworkers demonstrated that disruption 
of the gene encoding for PD-1 in mice caused dilated 
cardiomyopathy.33 They concluded that PD-1 may be 
an important receptor contributing to autoimmune 
diseases.
Several mouse models of T cell-dependent myocarditis 
exist. In a model of CD8+ T cell myocarditis, IFN-γ induced 
the overexpression of PD-L1 on endothelial cells.38 
Genetic deletion of PD-L1/PD-L2, as well as treatment 
with anti-PD-L1, transformed transient myocarditis into 
lethal disease. Deletion of PD-L1 in murphy Roths Large 
(MRL) mice (genetically predisposed to autoimmunity) 
resulted in lethal autoimmune myocarditis.39 Similarly, 
PD-1 deficiency in MRL mice causes a fatal myocarditis,40 
reminiscent of CTLA-4-deficient mice.55 In two models 
Figure 3 Some of the immune-related adverse effects (IRAEs) associated with checkpoints inhibitors in patients with cancer. 
DRESS, drug rash with eosinophilia and systemic symptoms.
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of T cell-dependent myocarditis, PD-1 protected against 
inflammation and myocyte damage.41
Recently, the role of PD-1/PD-L1 has been explored 
in models of cardiac ischaemia-reperfusion injury and 
myocardial infarction. Isolated ischaemic-reperfused rat 
hearts showed increased expression of PD-1 and PD-L1 in 
cardiomyocytes.70 Interestingly, PD-1 and PD-L1 were not 
coexpressed on the same myocytes. Furthermore, myocar-
dial infarction in BALB/c mice increased the percentage 
of PD-1+ and PD-L1+ cardiac cells. These experimental 
studies suggest that PD-1/PD-L1 and CTLA-4 play 
important roles in limiting T cell-mediated autoimmune 
myocarditis.
cardIac toxIcIty of checkpoInt InhIbItors In patIents 
wIth cancer
With few recent exceptions,118–121 the vast majority 
of papers on the toxicities of checkpoint inhibi-
tors have underestimated or even neglected cardiac 
toxicity.87 114 115 117 In a multicentre retrospective study 
on 752 patients with melanoma treated with ipilimumab, 
one case of myocardial fibrosis was reported.122 One case 
report revealed left ventricular dysfunction123 and one 
case of Takotsubo cardiomyopathy after treatment with 
ipilimumab.44 Interestingly, a late-onset ipilimumab-in-
duced pericarditis was reported in a patient with mela-
noma.124 In a multicentre study, six cases of cardiotoxicity 
after ipilimumab were identified.30 Two out of six cases 
were fatal despite intensive treatment. In the same series, 
one case of myocarditis after ipilimumab plus nivolumab 
and one case of cardiac arrest after pembrolizumab were 
described. A case of cardiac arrest was reported in a clin-
ical trial of ipilimumab in melanoma110 and a fatal case of 
myocardial infarction in a patient with NSCLC treated with 
pembrolizumab.16 Similar case reports have confirmed 
these findings outside the clinical trial setting.125 126 
Autoimmune myocarditis with variable severity has been 
described.127 128 In a multicentre, phase II, non-controlled 
study on 26 patients with advanced Merkel cell carcinoma 
treated with pembrolizumab, adverse events occurred in 
77% of patients and one case of myocarditis was reported 
after the first dose of pembrolizumab.15 Thus, a number of 
cardiotoxic events (myocarditis, HF, heart block, myocar-
dial fibrosis and cardiomyopathy) were documented in 
these groups of patients.
Recently, two cases of fulminant myocarditis and 
myositis associated with combination of ipilimumab plus 
nivolumab were carefully described.36 Despite intensive 
treatment, these two cases were fatal after receiving the 
first doses of checkpoint inhibitors. Both patients with 
melanoma had hypertension, but did not display other 
cardiac risk factors. Histological analysis demonstrated 
lymphocytes (CD4+ and CD8+ T cells) and macrophages 
infiltrating the myocardium, the cardiac sinus and the 
atrioventricular nodes. PD-L1 was highly expressed 
on injured cardiomyocytes and on infiltrating CD8+ 
T cells. Figure 4 (reproduced with permission from 
Johnson et al36) illustrates the ECGs and the histological 
findings of the heart of patient 2 described by Johnson and 
collaborators. Importantly, the overexpression of PD-L1 
in the injured myocardium in the two patients described 
by Johnson and collaborators is consistent with the consti-
tutive expression of PD-L1 in human heart34 35 and its 
upregulation in T cell-mediated myocarditis in mice.38 
Recently, PD-1 and PD-L1 were detected on rat cardio-
myocytes and overexpressed in the ischaemic-reperfused 
heart.70 An analysis of T cells infiltrating the myocardium, 
skeletal muscle and tumour revealed clonality of TCR. 
The authors suggested that common antigens present 
in these tissues could be recognised by clonal lympho-
cytes. Moreover, overexpression of IFN-γ, granzyme B and 
TNF-α, presumably produced by activated T cells, might 
contribute to cardiac damage.
The authors also assessed the frequency of myocarditis 
in the safety databases of Bristol-Myers Squibb Corpo-
rate to verify the occurrence of events in patients treated 
with nivolumab, ipilimumab or both. Among 20 594 
patients treated with these checkpoint inhibitors, 18 
drug-related severe adverse events of myocarditis were 
reported (0.09%). Combination therapy with both drugs 
was associated with more severe and frequent myocar-
ditis than those who received nivolumab alone (0.27% vs 
0.06%).36 Myocarditis, diagnosed at a median of 17 days 
after the first treatment, suggests the occurrence of early 
cardiotoxicity.
In conclusion, although combined immune checkpoint 
inhibition has produced durable antitumour responses in 
a percentage of patients with different tumours, IRAEs 
required discontinuation in nearly 40% of patients.89 90 
Most of these events are manageable with a high dose 
of glucocorticoids, although severe and even fatal events 
have occurred in rare instances. Better characterisation of 
the real incidence of cardiovascular toxicity of checkpoint 
blockers, alone and in combination, even if uncommon, 
is a major priority.
It is important to note that extensive cardiac moni-
toring, including the assessment of troponin, a sensitive 
and specific marker of cardiotoxicity,129 130 is not routinely 
performed in most immunotherapy trials. Therefore, the 
real incidence of early and late cardiotoxicity associated 
with immune checkpoint blockade is largely unknown.
management of myocardItIs assocIated wIth IcIs
Oncologists and cardiologists should be aware of early 
onset of myocarditis, in patients treated with ICIs alone 
and in combination. Our understanding of the patho-
physiology of myocarditis comes largely from animal 
studies.131 In the 2000s it was demonstrated that deletion 
of CTLA-4 and PD-1 axis can cause autoimmune myocar-
ditis.33 37 Myocarditis is an insidious disease with a wide 
spectrum of clinical presentation reflecting the different 
aetiologies and the variability of local or diffuse involve-
ment. In addition, patients with systemic autoimmune 
disorders (eg, rheumatoid arthritis, lupus erythematosus, 
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psoriatic arthritis, systemic sclerosis, vasculitis, polymy-
ositis) can have subclinical myocarditis. In the absence 
of specific studies, clinical experience should guide the 
use of checkpoint inhibitors in patients with cancer with 
pre-existing autoimmune diseases.132
Similarly, at present there is urgent need of validated 
guidelines for treatment of myocarditis associated with 
checkpoint inhibitors. Wang and coworkers118, based on 
their extensive personal experience, have proposed an 
interesting algorithm for management of myocarditis 
in patients treated with checkpoint inhibitors. Their 
algorithm represents an excellent basis for an urgently 
needed consensus guideline for management of different 
forms of immune-mediated myocarditis.
concludIng remarks
Checkpoint blockade has introduced clinical benefits 
by inducing regression of advanced metastatic tumours, 
improving patient survival and inducing durable effects 
in a percentage of patients with a broad spectrum of 
cancer types. Although IRAEs associated with monoclonal 
Figure 4 ECG and histological findings of the heart in a 63-year-old man with metastatic melanoma who developed fulminant 
lymphocytic myocarditis following initial doses of nivolumab and ipilimumab and who developed complete heart block.36 
Despite intense treatment (intravenous methylprednisolone 1 g/kg daily for 4 days plus infliximab 5 mg/kg), fatal complete heart 
block occurred. Initial right bundle branch block (RBBB) and ST depression (A) progressed rapidly to complete heart block and 
cardiac arrest (B). Autopsy showed lymphocytic infiltration in myocardium (C) comprised CD3+ T cells (D), many of which were 
CD8+ lymphocytes (E) and CD68+ macrophages (F) (adapted with permission from Johnson et al36).
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anti-CTLA-4 and anti-PD-1/PD-L1 antibodies are common 
and usually reversible, increasing reports of severe cardiac 
toxicity introduce important questions relevant for future 
oncology trials and clinical practice.
Patients with autoimmune disorders are usually 
excluded from clinical trials with checkpoint inhibitors. 
Patients with a wide spectrum of autoimmune disorders 
presumably represent 20–50 million people in the USA 
alone.119 In addition, approximately 14% of patients 
with lung cancer have a concurrent diagnosis of auto-
immune disease.133 These findings indicate that clinical 
and subclinical autoimmune disorders are an important 
consideration before initiation of checkpoint inhibitor 
therapy. In 12 patients treated with ipilimumab, worsening 
or exacerbation of pre-existing autoimmune diseases was 
observed in 50% of cases.134 135 Recently, Johnson and 
collaborators reported their experience with two groups 
of patients with pre-existing autoimmune disease and 
melanoma treated with ipilimumab or anti-PD-1.36 132 
Although 20%–30% of these patients experienced an 
autoimmune flare, the authors concluded that treatment 
with either ipilimumab or anti-PD-1 is feasible for patients 
with certain types of pre-existing autoimmunity.119 Given 
the heterogeneity of autoimmune disorders and the wide 
spectrum of their severity, specific guidelines regarding 
exclusion criteria and treatment are urgently needed.
Cardiac parameters and levels of troponins are not 
routinely evaluated in most oncology trials. Therefore, 
the true incidence of cardiac toxicity associated with 
checkpoint inhibitors may be higher in the real-world 
population.
Combination therapies such as combined checkpoint 
inhibitors, or sequential therapies with conventional 
chemotherapy plus checkpoint inhibitors, or checkpoint 
inhibitors plus antiangiogenic agents are increasingly 
being used.136 137 Cardiovascular monitoring is necessary 
to assess the occurrence of early and late cardiac toxicity 
associated with these newer cancer immunotherapies. 
The use of ICIs is expected to increase within the next 
years for treatment of new tumour types and presumably 
also for other immune-mediated disorders such as HIV138 
and infectious diseases.139 Therefore, prospective cardio-
vascular evaluation appears necessary to detect potential 
cardiotoxicity in these disorders.
All cases of cardiotoxicity associated with checkpoint 
inhibitors reported so far occurred immediately after the 
infusion or during the first year of therapy.15 30 36 44 Prospec-
tive studies should assess whether late-onset chronic 
cardiotoxicity can occur after completion of therapy.
Interestingly, interindividual differences in intestinal 
microbiota are a source of the heterogeneity in immuno-
therapeutic efficacy and toxicity of ICIs in cancer.7 140 141 
It will be important to investigate whether gut microbiota 
can also influence cardiac toxicity of ICIs.
Constitutive expression of PD-1 and PD-L1 occurs in 
human and murine myocytes.34 35 70 In addition, over-
expression of PD-L1 on the surface of injured myocytes 
has been demonstrated in patients with fulminant 
myocarditis treated with checkpoint inhibitors.36 The 
latter observations open the possibility that, in certain 
clinical conditions (eg, myocardial ischaemia), cytokines 
and chemokines produced by infiltrating immune cells 
can upregulate PD-1/PD-L1 pathway in human myocar-
dium. Additional in vitro and in vivo research is urgently 
needed to understand the immunological and molecular 
mechanisms underlying the development of these cardiac 
toxicities.
Today, oncologists and cardiologists work together 
mainly to detect and manage cardiotoxicity of antineo-
plastic treatments. Cardiologists are not always involved 
in the initial anticancer treatment planning or in the 
assessment of early cardiac dysfunction. With a growing 
number of patients treated with different types of ICIs, a 
collaboration of oncologists, cardiologists and immunol-
ogists is now necessary for a better characterisation of the 
mechanisms of cardiotoxicity of this novel class of anti-
cancer drugs and for a comprehensive identification and 
management of patients at risk for cardiac adverse events.
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